Sequence: YTIWMPENPRPGTPCDIFTNSRGKRASNG+RRRRRRRRR
| Experiment Id | EXP001288 |
|---|---|
| Paper | Attachment of Cell-Binding Ligands to Arginine-Rich Cell-Penetrating Peptides Enables Cytosolic Tran |
| Peptide | RVG-9DR |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 1–5 µM (ratios 5–25; typically 10:1 used) |
| Rna Concentration | ~200 nM (100 pmol in 0.5 mL for Neuro2a); Jurkat 100 pmol in 0.2 mL (~500 nM) |
| Mixing Ratio | 10:1 (peptide:siRNA molar) |
| Formulation Format | electrostatic peptide:siRNA complex |
| Formulation Components | RVG-9DR + siRNA (noncovalent complex) |
| Size Nm | 208.60 |
| Zeta Mv | -24.20 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Neuro2a (mouse neuroblastoma; GFP-expressing) |
| Animal Model | |
| Administration Route | in vitro (cell incubation) |
| Output Type | gene knockdown (GFP reporter) |
| Output Value | GFP-negative cells increased by 42.1 ± 23.4% vs siGFP alone |
| Output Units | |
| Output Notes | Enhanced uptake at 10:1 (MFI 627 ± 124). Live imaging shows cytosolic translocation and membrane inversion at binding sites; endosomal proteolysis implicated. |
| Toxicity Notes | Transient annexin V positivity during membrane inversion without loss of membrane integrity/cytotoxicity (LDH and Alamar Blue assays; data not shown). |
| Curation Notes |